# FUMANBA-2 (NCT05181501)

> A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05181501
- Phase: PHASE1
- Status: NOT_YET_RECRUITING
- Sponsor: Nanjing IASO Biotechnology Co., Ltd.
- Conditions: Multiple Myeloma
- Interventions: Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)
- Enrollment: 20
- Primary outcome: Proportion of Minimal Residual Disease (MRD)-negative subjects
- Primary outcome: Median progression-free survival (mPFS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=fumanba-2-nct05181501